Anti-angiogenic drugs

Research output: Contribution to journalArticlepeer-review

Abstract

Angiogenesis, the formation of neo-vessels, is a physiological event but is involved in various pathological conditions including cancers. Thus, the establishment of effective anti-angiogenic treatment has long been a goal. The recent development of bevacizumab, a neutralizing monoclonal antibody against VEGF, as the first anti-angiogenic drug, validated the clinical benefit of the inhibition of tumor angiogenesis. Thereafter, various drugs targeting VEGF-mediated signals have been developed to control tumor angiogenesis. Anti-angiogenic therapy is now considered a major step forward in cancer treatment at the clinical level.

Original languageEnglish
Pages (from-to)1072-1075
Number of pages4
JournalJapanese Journal of Cancer and Chemotherapy
Volume36
Issue number7
Publication statusPublished - 2009 Jul

Keywords

  • HIF-1
  • VEGF
  • VEGFR2
  • mTOR

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Anti-angiogenic drugs'. Together they form a unique fingerprint.

Cite this